Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background: Although different antiplatelet agents are used for the prevention of thrombosis and treatment of ischemic heart
disease, very little information regarding therapeutic potential of these agents in heart failure is available.
Objectives: We have investigated the effects of some antiplatelet agents such as sarpogrelate (SAR) and cilostazol (CIL) treatments
on cardiac dysfunction, cardiac remodeling and subcellular defects in heart failure due to myocardial infection.
Methods: Heart failure in rats was induced by including the coronary artery for 8 weeks and the drug treatment was started 4
weeks after inducing myocardial infarction.
Results: Marked depression in cardiac output and ejection fraction as well as increases in heart rate, left ventricle (LV) thickness
and LV volume in the infarcted animals were attenuated by SAR and CIL. Alterations in myofibril Ca2+-ATPase, as well as myosin
isozyme contents and gene expression in the failing heart were reduced by SAR and CIL. Likewise, changes in sarcoplasmic
reticular Ca2+-uptake and release activities, Ca2+-pump and Ca2+-release protein content as well as their mRNA levels were
attenuated by both drug treatments.
Conclusions: These results provide evidence that both SAR and CIL delay the progression of heart failure and improve cardiac
function by attenuating cardiac remodeling, subcellular defects and abnormalities in cardiac gene expression. It is suggested that
antiplatelet agents may prove to be a viable therapy for the treatment of heart failure. (Infrastructure support for this study was
provided by the St. Boniface Hospital Foundation)
Recent Publications
1. Dhalla N S, Takeda N, Rodriguez-Leyva D and Elimban V (2014) Mechanisms of subcellular remodelling in heart
failure due to diabetes. Heart Fail Rev 19(1):87-99.
2. Dhalla N S, Rangi S, Babick A P, Zieroth S and Elimban V (2012) Cardiac remodeling and subcellular defects in heart
failure due to myocardial infarction and aging. Heart Fail Rev 17(4-5):671-681.
3. Machackova J, Sanganalmath S K, Elimban V and Dhalla N S (2011) β-adrenergic blockade attenuates cardiac
dysfunction and myofibrillar remodeling in congestive heart failure. J Cell Mol Med 15(3):545-554.
4. Dhalla N S, Saini-Chohan H K, Rodriguez-Leyva D, Elimban V, Dent M R and Tappia P S (2009) Subcellular remodeling
may induce cardiac dysfunction in congestive heart failuren. Cardiovasc Res 81(3):429-438.
Biography
Naranjan S Dhalla is a Distinguished Professor and Director of Cardiovascular Developments, St. Boniface Hospital Albrechtsen Research Centre, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, and Winnipeg, Canada.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals